↓ Skip to main content

Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies

Overview of attention for article published in Frontiers in oncology, May 2021
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
2 X users
patent
1 patent

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
65 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies
Published in
Frontiers in oncology, May 2021
DOI 10.3389/fonc.2021.680834
Pubmed ID
Authors

Yuming Zhao, Dengyang Zhang, Yao Guo, Bo Lu, Zhizhuang Joe Zhao, Xiaojun Xu, Yun Chen

Abstract

Receptor tyrosine kinase ROR1 plays an essential role in embryogenesis and is overexpressed in many types of malignant tumors. Studies have demonstrated that it plays an important role in oncogenesis by activating cell survival signaling events, particularly the non-canonical WNT signaling pathway. Antibody-based immunotherapies targeting ROR1 have been developed and evaluated in preclinical and clinical studies with promising outcomes. However, small molecule inhibitors targeting ROR1 are underappreciated because of the initial characterization of ROR1 as a peusdokinase. The function of ROR1 as a tyrosine kinase remains poorly understood, although accumulating evidence have demonstrated its intrinsic tyrosine kinase activity. In this review, we analyzed the structural and functional features of ROR1 and discussed therapeutic strategies targeting this kinase.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 65 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 15%
Student > Ph. D. Student 6 9%
Student > Master 5 8%
Other 2 3%
Student > Postgraduate 2 3%
Other 4 6%
Unknown 36 55%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 11 17%
Agricultural and Biological Sciences 5 8%
Immunology and Microbiology 3 5%
Chemistry 3 5%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 4 6%
Unknown 38 58%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2024.
All research outputs
#7,966,302
of 25,392,582 outputs
Outputs from Frontiers in oncology
#2,906
of 22,433 outputs
Outputs of similar age
#167,183
of 459,934 outputs
Outputs of similar age from Frontiers in oncology
#165
of 1,385 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 22,433 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 459,934 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 1,385 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.